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Abstract
Lung cancer is the leading cause of cancer deaths in the
United States. Current therapies are inadequate. Histone
deacetylase inhibitors (HDACi) are a recently developed
class of anticancer agents that cause increased acetyla-
tion of core histones and nonhistone proteins leading to
modulation of gene expression and protein activity in-
volved in cancer cell growth and survival pathways.
We examined the efficacy of the HDACi panobinostat
(LBH589) in a wide range of lung cancers and mesothe-
liomas. Panobinostat was cytotoxic in almost all 37 can-
cer cell lines tested. IC50 and LD50 values were in the
low nmol/L range (4–470 nmol/L; median, 20 nmol/L).
Small cell lung cancer (SCLC) cell lines were among
the most sensitive lines, with LD50 values consistently
<25 nmol/L. In lung cancer and mesothelioma animal
models, panobinostat significantly decreased tumor
growth by an average of 62% when compared with ve-
hicle control. Panobinostat was equally effective in
immunocompetent and severe combined immunodeficien-
cy mice, indicating that the inhibition of tumor growth by
panobinostat was not due to direct immunologic effects.
Panobinostat was, however, particularly effective in SCLC
xenografts, and the addition of the chemotherapy agent
etoposide augmented antitumor effects. Protein analysis
of treated tumor biopsies revealed elevated amounts of cell
cycle regulators such as p21 and proapoptosis factors,
such as caspase 3 and 7 and cleaved poly[ADP-ribose] po-
lymerase, coupled with decreased levels of antiapoptotic
factors such as Bcl-2 and Bcl-XL. These studies together
suggest that panobinostat may be a useful adjunct in the
treatment of thoracic malignancies, especially SCLC. [Mol
Cancer Ther 2009;8(8):2221–31]
Introduction
Lung cancer has a worldwide incidence of 1.2 million cases.
In the United States the annual death rate due to this disease
for 2006 (162,460) approximated its annual incidence rate
(174,470), making it the leading cause of cancer deaths in
both men and women in the United States (17.8%). Meso-
thelioma represents 1.5% of these cases, and small cell lung
cancer (SCLC) accounts for approximately 13%, with non–
small cell lung cancer (NSCLC) being responsible for the
rest (1). Given the overall poor survival rates despite treat-
ment, and with only little to modest progress achieved to
date in the development of effective treatments, there is a
clear need for new therapeutic approaches.
Histone deacetylase inhibitors (HDACi) are a recently de-
veloped class of anticancer agents. These agents inhibit the
deacetylation both of histones and nonhistone cellular pro-
teins, inducing hyperacetylation and an “open chromatin”
state leading to increased transcriptional activity. HDAC
inhibition leads to modulation of gene expression leading
to the reexpression of silenced tumor suppressor genes, cell
cycle arrest, terminal differentiation, and apoptosis (2). In
addition, HDAC inhibition can target nonhistone proteins
involved in cancer cell growth and survival pathways.
The antitumor effects of HDACi have been shown in a
variety of cancer cell lines (NSCLC, prostate, colon, ovarian,
breast, bladder, pancreas, leukemias, and lymphomas),
in vivo tumor models, and in patients with both hematologic
and solid tumors (2).
This study focuses on the use of a new pan-HDACi, pa-
nobinostat, a cinnamic hydroxamic acid analog (class II
HDACi). This agent has been shown to exert antitumor ef-
fects on a variety of cancer cell lines (3–5) and is currently
being investigated in clinical trials in patients with ad-
vanced solid tumors (such as hormone refractory prostate
cancer, breast, clear renal cell, colorectal, bladder, and ovar-
ian cancers) and hematologic malignancies (6, 7). A large
clinical trial with another HDACi, suberoylanilide hydroxa-
mic acid (SAHA), for treating mesothelioma is ongoing.
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To date, the effects of panobinostat on cell lines derived
from thoracic malignancies (mesothelioma, NSCLC,
SCLC) have not been systematically characterized. Our
goal was to examine the efficacy of panobinostat in a
wide range of thoracic malignancies using both in vitro
and in vivo models. We therefore screened a panel of 37
cell lines drawn from all three types of thoracic malignan-
cies. Although the growth of most cell lines was inhibited
in this pilot screen, we found that SCLC cell lines were
especially sensitive to this compound. Animal studies
confirmed these results, suggesting that panobinostat




Mesothelioma Cells Lines. The human mesothelioma
cell lines OK-2 (SF151720), OK-4 (SF080125B), OK-5
(SF161815), and OK-6 (SF160520) were provided by the
Stehlin Foundation (8). The human REN, LRK, and M30 cell
lines were derived at the University of Pennsylvania from
mesothelioma tumor tissues from individual patients.
H513 cells were purchased from the American Type Culture
Collection. The murine AB-1, AC29, AB12, and AE17-ova
cell lines (provided by Drs. Bruce Robinson and Delia
Nelson, University of Western Australia) were derived from
mesothelioma tumors arising in mice that were first given
i.p. administrations of asbestos (9, 10). OK-2, OK-4, OK-5,
OK-6, REN, M30, and AE17 cells were cultured in RPMI
1640 (Gibco Invitrogen) supplemented with 10% fetal bo-
vine serum (FBS; FBS Premium select, Atlanta Biologicals).
H513 cells were cultured in RPMI 1640 supplemented with
5% FBS. LRK, AB-1, AC29, and AB12 cells were cultured in
DMEM (Gibco) supplemented with 10% FBS.
NSCLC Cell Lines. The human NSCLC lines H1299,
A549, H460, H1264, H322, and H661, and the murine
NSCLC lines LLC and L1C2 were purchased from the
American Type Culture Collection. L55 was derived at
the University of Pennsylvania from the NSCLC of a
patient. The murine TC-1 cell line (11) was provided by
Dr. Yvonne Paterson (University of Pennsylvania), and
the LKR cell line, derived from a tumor which developed
in a transgenic mouse expressing an activated Kras gene
(12), was provided by Dr. Joseph Friedberg (University of
Pennsylvania). All cell lines were cultured in RPMI 1640
supplemented with 10% FBS with the exception of LLC,
L1C2, and LKR cells, which were cultured in DMEM
supplemented with 10% FBS.
SCLC Cell Lines. RG-1, LD-T, H209, GL-E, H209/CP,
BK-T, LV-E, TY-E, HG-E, SH-A, AD-A, and SM-E cells were
all derived from the individual tumors of patients with
SCLC (13). H526 and H69 cells were purchased from the
American Type Culture Collection. All cell lines were
cultured in RPMI 1640 supplemented with 5% FBS.
All cell culture media formulations were supplemented
with 2 mmol/L L-glutamine, 100 U/mL of penicillin, and
100 μg/mL of streptomycin (all from Gibco). All the cell
lines were maintained at 37°C in a humidified atmosphere
with 95% air: 5% CO2.
Reagents
Panobinostat (formerly called LBH589), a HDACi, was
provided by Novartis Pharmaceuticals in suspension with
5% dextrose. The HDACi SAHA was kindly provided by
Dr Xiaobo Cao, from M. D. Anderson. Etoposide (a topoi-
somerase II inhibitor) was purchased from Sigma-Aldrich.
Cell Proliferation MTS Assays
The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTT) cell prolif-
eration assays (Promega) were carried out for 37 cell lines
(12 mesothelioma cell lines, 11 NSCLC cell lines, and 14
SCLC cell lines). Briefly, cells were plated in quadruplicate
in 96-well plates at a confluence of approximately 70%.
Cells were incubated overnight and panobinostat or
SAHA was then added the following day. The cells re-
mained exposed to each drug for the entire testing period;
no new drug was subsequently added. Concentrations of
drug tested ranged from 0 to 800 nmol/L for panobinostat
and from 0 to 25 μmol/L for SAHA. The MTS reagents
were added, and plates were read on a multiwell scanning
spectrophotometer 48 and 72 h after drug exposure.
For panobinostat, the IC50 and LD50 were determined and
comparedwith that of SAHA in selected cell lines. IC50was cal-
culated as the concentration of the compound at which 50% of
cells were growth-inhibited compared with vehicle treatment.
LD50 was the concentration at which 50% of cells originally
plated were killed. A standard curve with known numbers of
control cells was includedwith every assay and assayed under
identical conditions as the experimental groups. The assays
were repeated to ensure consistency of results.
Fluorescent Activated Cell Sorting Analysis for Cell
Cycle Status and Cellular Viability
Cell cycle status and cellular viability were determined
via fluorescent activated cell sorting analysis of DNA con-
tent as previously described (14). Briefly, H69 cells were
plated and mock-treated (control cells), or exposed to either
etoposide (34 μmol/L) or panobinostat (20 nmol/L) alone,
or in combination. The effects of the combination of etopo-
side and panobinostat added after 24 h and vice versa were
also tested. During fluorescent activated cell sorting, no gat-
ing was done during data acquisition on the propidium
iodide–stained nuclei in order to not exclude any cells from
the analysis, including those with sub-G1 content represen-
tative of nuclear fragmentation. The aggregate results were
then analyzed for the proportion of cells with DNA content
corresponding to each respective cell cycle phase.
Cells were harvested at different time points (from 0
to 60 h).
Immunoblotting
Tumor lysates were prepared by mechanical tissue
homogenization in lysis buffer [consisting of 50 mmol/L
Tris-HCl (pH 8), 150 mmol/L NaCl, 1% NP-40, 0.5% sodium
deoxycholate, and 0.1% SDS supplemented with a protease
inhibitor cocktail (Mini Complete, Roche)]. The protein con-
centrations of the supernatants were quantified via the BCA
Protein Assay Kit (Pierce). Twenty micrograms of lysate
HDACi and Lung Cancer
Mol Cancer Ther 2009;8(8). August 2009
2222
were mixed with SDS buffer (1× LDS sample buffer plus 1×
sample reducing agent; Invitrogen) and were loaded into
each lane of a 4% to 12% SDS-polyacrylamide gel. After
electrophoresis, the proteins were transferred onto a polyvi-
nylidene fluoride membrane (Perkin Elmer). The mem-
branes were subsequently blocked with PBS containing
5% nonfat dry milk, and then probed with primary antibo-
dies overnight at 4°C. The following primary antibodies and
dilutions were used: anti-β-actin (1:10,000; Sigma-Aldrich),
anti-Bcl-XL (1:1,000; Santa Cruz Biotechnology), anti-Bid
(1:500; Becton Dickinson Pharmingen), anti-p21 (1:1,000;
Santa Cruz), anti-Bcl-2 (1:100; Dako Cytomation), anti-
acetylated histone H4 (AH4; 1:1,000; Upstate Biotechnolo-
gy), anti-acetylated histone H3 (AH3; 1:5,000; Upstate
Biotechnology), anti–cleaved caspase 3 (1:1,000; Cell Signal-
ing), anti–cleaved caspase 7 (1:1,000; Cell Signaling),
anti–poly[ADP-ribose] polymerase (PARP; 1:1,000; Cell Sig-
naling), and anti-α-tubulin (1:5,000; Sigma-Aldrich). The
membranes were washed repeatedly in PBS containing
0.5% milk and 0.2% Tween-20, and then incubated for
1 h with polyclonal horseradish peroxidase–conjugated
secondary antibodies (1:10,000; donkey anti-rabbit or don-
key anti-mouse antibody, from Jackson ImmunoResearch
Laboratories). After further washes, enhanced chemilumi-
nescence was done on the membranes with the Western
Lightning Chemiluminescence Reagent Plus (Perkin Elmer),
prior to exposure to film. Three separate tumor biopsies
were analyzed from each treatment condition.
In vivo Experiments
The experiments done on the mice were in accord with a
protocol reviewed and approved by the Institutional Ani-
mal Care and Usage Committee at the University of Penn-
sylvania, which was in compliance with the Guide for the
Care and Use of Laboratory Animals. AE17 and TC-1 can-
cer cells (1 × 106 cells) were injected into the flanks of adult
female C57Bl/6 mice (Taconic Labs) and severe combined
immunodeficiency (SCID) mice (Jackson Laboratories).
M30 (10 × 106 cells), A549 (5 × 106 cells), H69 (2.5 × 106
cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106)
cells were also injected, but in the presence of matrigel
(BD Biosciences), into the flanks of SCID mice. There were
5 to 10 mice in each treatment group. The experiments with
the A549 and H69 cell lines were repeated to ensure the sta-
tistical consistency of the results. Experiments were terminat-
ed when the tumors in the control mice had grown to a size
that threatened the quality of life of the mice.
When tumors reached 100 to 500 mm3, panobinostat
was administered via i.p. injections (10–20 mg/kg) on a
daily schedule (5-days-on, 2-days-off regimen) for the en-
tire duration of the experiment. Control mice received i.p.
injections with dextrose 5% in water (“vehicle treatment”).
Every tumor was measured with a caliper at least twice
weekly. For evaluation of the effects of combination ther-
apy on SCLC-derived tumors, SCID mice with H69 tu-
mors were administered panobinostat as described
above. Three days after the initiation of panobinostat,
and again 1 wk later, etoposide (40 mg/kg) was admin-
istered i.p.
Statistical Analysis
Statistical analyses were done using the Prism statistical
package. Student's t-test or χ2 analyses were utilized to
compare results between treatment groups. The Kruskal-
Wallis one-way ANOVA by ranks with posthoc Dunn's test-
ing was used for the experiments with more than two
groups. P < 0.05 was considered statistically significant.
Error bars in the graphs represent SE calculated with
Microsoft Excel.
Results
Panobinostat Has Potent In vitro Growth Inhibitory
and Cytotoxic Effects in Thoracic Cancer Cell Lines
The effects of panobinostat on the inhibition of cancer
cell growth (IC50) were determined in a wide range of hu-
man and murine lung cancer (NSCLC and SCLC) and
mesothelioma cell lines via MTS assays (Table 1). We also
measured the ability to induce cell death (LD50) in many
of the cell lines. Panobinostat exhibited potent antiproli-
ferative activity and cytotoxicity in seven human and four
murine NSCLC cell lines. For the human NSCLC cell
lines, the IC50 ranged from 5 to 100 nmol/L, with a me-
dian value of 35 nmol/L (except for the cell line H661).
The LD50 ranged from 50 to 400 nmol/L, with a median
value of 105 nmol/L. For the murine NSCLC cell lines,
the IC50 ranged from 20 to 310 nmol/L, with a median
value of 87.5 nmol/L, and the LD50 ranged from 75 to
690 nmol/L, with a median value of 200 nmol/L.
The antiproliferative and cytotoxic effects of panobinostat
were then studied in eight human and four murine meso-
thelioma cell lines. As shown in Table 1, mesothelioma
(Meso) cell lines tended to be more sensitive than NSCLC
lines to panobinostat. For the human Meso cell lines, the
IC50 ranged from 5 to 50 nmol/L, with a median value of
30 nmol/L, and the LD50 ranged from 5 to 620 nmol/L,
with a median value of 45 nmol/L. For the murine Meso cell
lines, the IC50 ranged from 20 to 470 nmol/L, with a median
value of 32.5 nmol/L.
SCLC cell lines showed the highest sensitivity to panobi-
nostat. As shown in Table 1, the IC50 for all but one of the 14
human SCLC cell lines was <25 nmol/L, with a median of
9.5 nmol/L; in fact, 10 of 14 SCLC lines showed an IC50 of
≤10 nmol/L. The LD50 ranged from 6 to 25 nmol/L, with a
median value of 12 nmol/L. The SCLC line H209/CP (a
variant of H209 cells that has developed cisplatinum resis-
tance) showed very similar IC50 and LD50 values when com-
pared with the parental cisplatinum-sensitive H209 cell line,
results suggesting that panobinostat may usefully overcome
chemotherapy resistance in SCLC cell lines.
Finally, in selected cell lines, we compared panobinostat
with SAHA, another HDACi currently in clinical trials.
The LD50 of SAHAwere 10- to 1,000-fold higher than those
seen with panobinostat (Table 1).
To further explore the increased sensitivity of SCLC lines
to panobinostat, we assessed the time course of cell cycle
effects invoked by exposure to panobinostat. H69 cells
exposed to panobinostat showed accumulation of cells with
Molecular Cancer Therapeutics
Mol Cancer Ther 2009;8(8). August 2009
2223
G2-M DNA content, which was initially coincident with but
eventually was superseded by the proportion of nonviable
cells (marked by sub-G1 DNA content; Fig. 1A). With sus-
tained exposure to panobinostat, e.g. 60 hours of exposure,
>70% of the cells had become nonviable.
The rate of cell death induced by panobinostat could also
be accelerated by combined treatment with etoposide, a
standard chemotherapeutic agent for SCLC. Whereas near
complete eradication of H69 cells with panobinostat alone
required ≥60 hours of continuous exposure, a comparable
degree of cell death with only 36 hours of panobinostat ex-
posure was achieved if the cells were pretreated with etopo-
side for 12 hours (compare the last bar graph in Fig. 1Awith
last bar graph in Fig. 1B). The proportion of cells killed by
the combination treatment was also significantly greater
than with either etoposide or panobinostat alone for the full
48 hours of the experiment (Fig. 1B and C). Interestingly,
pretreatment with etoposide before the addition of panobi-
nostat seemed to be more effective at rapidly killing cells
than panobinostat followed by etoposide.
Panobinostat Significantly Slows the In vivo Growth
of Tumors Derived from Meso and NSCLC Cells
We next tested the effects of doses between 10 and 20
mg/kg of panobinostat (given i.p., 5 days/week) on select-
ed cell lines grown as flank tumors in mice, including the
human Meso cell line M30 (grown in SCID mice; Fig. 2A),
the mouse Meso cell line AE17 (grown in syngeneic C57/B6
mice; Fig. 2B), the human NSCLC line A549 (grown in SCID
mice; Fig. 2C), and the mouse NSCLC line TC1 (grown in
C57/B6 mice; Fig. 2D). Although tumor regression was
Table 1. IC50 of NSCLC, mesothelioma, and SCLC lines to panobinostat
Species Cell line Panobinostat SAHA LD50
IC50 (nmol/L) LD50 (nmol/L)
NSCLC Human H1299 5 120 >25 μmol/L
Human L55 11 80
Human A549 30 50
Human H460 40 90
Human H1264 100 250
Human H322 100 400
Human H661 >800
Mouse TC1 20 75 >800 nmol/L
Mouse LLC 85 200
Mouse L1C2 90
Mouse LKR 310 690
MESO Human OK-6 5 5 12 μmol/L
Human OK-5 7 7 1.5 μmol/L
Human LRK <10 30 >800 nmol/L
Human OK-4 25 60
Human M30 30 100
Human REN 30
Human H513 35
Human OK-2 50 620 14 μmol/L
Mouse AB-1 20
Mouse AE17-ova 25 80
Mouse AC29 40
Mouse AB12 470
SCLC Human RG-1 4 6
Human LD-T 5 11
Human GLE 8 8 800 nmol/L
Human H209 6 10
Human H209/CP 8 20
Human BKT 9 13
Human LVE 9
Human TY-E 10 19 3 μmol/L
Human H526 10 12
Human HG-E 10 12
Human SH-A 12
Human H69 20 25
Human ADA 25
Human SM-E 175
NOTE: Comparison of IC50 and LD50 of panobinostat for 37 lung cancer cell lines: 11 NSCLC cell lines (7 human, 4 mouse), 12 mesothelioma (MESO) cell lines
(8 human, 4 mouse), and 14 SCLC cell lines (all human). Selected cell lines were compared with SAHA. Note that most of the IC50 values are in the low
nmol/L range.
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not observed, panobinostat significantly slowed tumor
growth when compared with vehicle control for all four dif-
ferent in vivo models tested, and by an average of almost
60% (P < 0.05). Interestingly, there seemed to be no statisti-
cally significant differences among the effects of the 10, 15,
and 20 mg/kg doses for most of the tumors, with the excep-
tion of the tumors grown from the A549 cells, for which
the 20 mg/kg dose was clearly more efficacious than the
10 mg/kg dose. Finally, there was no increased mortality
or obvious toxicity noted with the panobinostat treatment
during the course of the experiments, except for mild
weight loss (<10%), and fur changes in the M30 cell study.
The experiments with the AE17 and TC-1 cells were
done in syngeneic animals with intact immune systems.
To test whether the therapeutic responses we observed
might be related to immune effects, we repeated the ex-
periments in immunodeficient SCID mice. The slowing of
tumor growth by panobinostat in the SCID mice was vir-
tually identical to that previously noted in immunocom-
petent C57/B6 mice (Supplementary Fig. S1), therefore
indicating that the inhibition of tumor growth caused
by panobinostat is not likely to be due to T-cell- or
B-cell-mediated immunologic effects.
Panobinostat Dramatically Slows the In vivo Growth
of Tumors Derived from SCLC Cells and Induces
Remissions
We next tested the effect of panobinostat on tumors de-
rived from four human SCLC cell lines grown as xenografts
in SCID mice. Panobinostat had a dramatic effect on all the
SCLC-derived tumors that was significant compared with
control animals with identically derived tumors but
mock-treated. Daily panobinostat, given i.p. at 20 mg/kg
for 5 days per week, resulted in an average decrease in
growth of 70% at the end of all the experiments. Compared
with the corresponding control tumors, panobinostat
resulted in a 53% decrease for H526-derived tumors
(Fig. 3A), a 81% decrease for BK-T–derived tumors (Fig. 3B),
a 76% decrease for RG-1–derived tumors (Fig. 3C), and
a 70% decrease for H69-derived tumors (Fig. 3D). In con-
trast to the lack of tumor regression noted in NSCLC and
Meso-derived xenografted tumors that were treated under
identical conditions and doses, panobinostat resulted in
Figure 1. The in vitro effects of panobinostat on H69 SCLC cells: time-dependent cell cycle changes and cytotoxicity. A, time-dependent cell cycle and
cytotoxic effects of panobinostat. Bar graphs, percentage of H69 cells in the respective phases of cell cycle after different exposure times to panobinostat,
as determined by DNA flourescent activated cell sorting (FACS). The proportion of cells with Sub-G1 DNA content progressively increased with increasing
exposure times to panobinostat. B and C, cell death is increased with combined panobinostat and etoposide. Bar graphs, respective percentages of H69
cells with Sub-G1 DNA content after exposure to panobinostat alone, etoposide alone, or combination of both agents. All cells were harvested after 48 h of
drug exposure. Panobinostat > Etoposide, cells were treated with panobinostat for 12 h before etoposide was added, and then exposed to both drugs for
an additional 36 h. Etoposide > Panobinostat, cells were treated with etoposide for 12 h before panobinostat was added, and then exposed to both drugs
for an additional 36 h. Cells treated with panobinostat only or etoposide only were treated continuously for 48 h. Either sequence of combination treatment
showed significantly greater proportions of nonviable cells than each of the drugs alone. Error bars are not available because these experiments did not
involve parallel plates processed in triplicate. Statistical significance of differences in the proportion of cells was evaluated by χ2 analysis. We repeated this
experiment three times, with all three experiments resulting in similar findings. *, statistically significant differences when compared with panobinostat
only or etoposide only (P< 0.01); C, DNA FACS histograms derived from the experiment described in Fig. 1B, showing the respective proportions of H69
cells in each of the cell cycle phases, after the indicated drug treatment (mock-treated controls, panobinostat alone, etoposide alone, or combination of
both agents). Bracket, proportion of nonviable cells with Sub-G1 DNA content.
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dramatic tumor regression in two of the SCLC-derived tu-
mors, with the size of the BK-T–derived tumors reduced
from an average of 296 mm3 at the beginning of the treat-
ment course to 116 mm3 at the end of the experiment, and
RG-1–derived tumors decreased from an average of 185
mm3 at the beginning of the treatment course to 86
mm3 at the end of the experiment.
Panobinostat Combines with Etoposide to Maximally
Inhibit the In vivo Growth of Tumors Derived from SCLC
Cells
Patients with SCLC are commonly treated with chemo-
therapy that includes the drug etoposide (VP16). Studies
have reported that HDACi exposure promotes histone hy-
peracetylation, resulting in a more accessible chromatin
structure that may be more susceptible to DNA-damaging
agents such as etoposide (15, 16), a mechanism that may un-
derlie the enhanced in vitro efficacy of combining panobino-
stat with etoposide that we noted for SCLC cell lines (Fig. 1).
We therefore studied the in vivo effects of combining these
two agents to treat tumors derived from SCLC cells. As
shown in Fig. 4, etoposide alone (40 mg/kg given i.p. week-
ly) did not slow tumor growth in all animals to a degree
significantly different than that in mock-treated animals. Pa-
nobinostat at 20 mg/kg (given i.p. on a daily basis) by itself
significantly reduced tumor growth, as we had previously
found in the experiments described in Fig. 3. However,
the combination of etoposide and panobinostat resulted in
the maximal antitumor effects that were significantly better
than either drug alone (P < 0.05).
Effects of Panobinostat on Histones and Nonhistone
Proteins; Modulation of Apoptosis-Related Components
In order to characterize the mechanisms that may under-
lie the antitumor effects of panobinostat, xenografts were es-
tablished with H69 human SCLC cells in SCID mice and
were subsequently treated as in the experiments described
in Fig. 4. As before, mice were injected with vehicle only
(control group), etoposide alone, panobinostat alone, or eto-
poside together with panobinostat (“combo” group). These
tumors were harvested from the mice at the end of the ex-
periment, 6 hours after the last dose of panobinostat and
24 hours after a dose of etoposide had been given and
processed for immunoblot analyses. As shown in the
respective columns of Fig. 5, acetylation of histone H3 and
H4 was markedly increased by panobinostat treatment, in-
dicating HDAC inhibition. Panobinostat was also associated
with marked up-regulation of the proapoptotic markers
t-Bid, cleaved PARP, cleaved caspase 3, and cleaved caspase
7; a marked decrease of the antiapoptosis factor Bcl-XL; and
a small increase in the cyclin-dependent kinase inhibitor
p21. Interestingly, compared with mock-treated controls,
Figure 2. The in vivo effects of panobinostat on mesothelioma and NSCLC cells growing in mice. Tumor cells were injected in the flank of appropriate
mice on day 0. Panobinostat treatment was started when tumors reached approximately 100 to 300 mm3. A, M30 mesothelioma xenograft model.
B, AE17 mesothelioma murine syngeneic model. C, A549 NSCLC murine xenograft model. D, TC1 NSCLC murine syngeneic model. *, P < 0.05,
between control and panobinostat treatment groups, except for Cwhere the statistical difference is present between control and 20 mg/kg dose treatment
group only. Arrow from “Panobinostat started” box indicates when panobinostat treatment was started.
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etoposide alone also led to a small increase of histone H4
acetylation and cleaved PARP. However, unlike panobino-
stat alone or in combination, etoposide alone did not dis-
cernibly increase histone H3 acetylation, or increase the
apoptosis-related t-Bid, caspase 3, or caspase 7.
We were especially interested in the relative effects of pa-
nobinostat combined with etoposide (i.e. combo treatment),
compared with controls and either panobinostat or etopo-
side alone, given that the antitumor efficacy with combo
treatment was more effective than either treatment alone.
We noted that combo treatment led to changes in proteins
similar to panobinostat alone, but with important differ-
ences. In particular, combo treatment led to near complete
eradication of the antiapoptotic factor Bcl-2 and maximal in-
crease in p21. Panobinostat alone had no effect on Bcl-2 and
only a small increase in p21.
Discussion
The unsatisfactory rate of cure with standard treatments for
disseminated thoracic malignancies has encouraged the de-
velopment of novel treatment strategies such as those in-
cluding histone deacetylase inhibitors. In vitro studies on
select NSCLC, SCLC, and mesothelioma cell lines have thus
been conducted with HDACi such as SAHA (17–20),
MGCD0103 (21), trichostatin-A (19, 22–27), MS-275 (28),
depsipeptide/FR901228 (29), trapoxin A (30), sodium buty-
rate (31), and valproic acid (32). A common finding has been
that HDACi inhibit cell growth and induce apoptosis in
these cell lines studied with varying degrees of efficacy.
In vitro mechanisms of cell death induced by these HDACi
have included activation of caspases, down-regulation of
antiapoptotic factors such as Bcl-2 and Bcl-XL, and up-
regulation of p21 (17, 18, 21, 22, 24, 27, 29, 31, 33–35). A
number of other studies have also suggested that HDACi
may affect antitumor immune responses (18, 36–38).
The wealth of published in vitro data has been accompa-
nied by relatively few in vivo studies of these agents in
animal models of tumors derived from thoracic malignan-
cies (21, 33). There have also been early reports incorporat-
ing HDACi in clinical trials, such as for NSCLC with
Pivanex (39) and Romidepsin (depsipeptide; ref. 40). A
large randomized trial of SAHA for mesothelioma (41) is
ongoing, and it is based on responses seen in an earlier
phase I trial (42).
Panobinostat (formerly known as LBH589) is a cinnamic
hydroxamic acid analog (class II HDACi) that has shown
activity for hematologic malignancies and cutaneous lym-
phomas (6, 7). However, studies involving panobinostat
Figure 3. The in vivo effects of panobinostat on SCLC cells growing in mice. SCLC tumor cells were injected in the flanks of SCID mice (murine
xenograft model) on day 0. Panobinostat treatment was started when tumors reached approximately 200 to 500 mm3. Cell lines H526 (A), BKT (B),
RG1 (C), and H69 (D). *, P < 0.05 between control and panobinostat treatment groups. Arrow from “Panobinostat stated” box indicates when
panobinostat treatment was started.
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for thoracic malignancies are still relatively sparse (33, 43).
We therefore sought to compare the effects of panobinostat
in a large panel of thoracic tumor cell lines, to test its effica-
cy in xenograft and syngeneic animal models, to study
whether combining panobinostat with chemotherapy may
result in superior efficacy, and to analyze the in vivo modu-
lation of histone and nonhistone proteins as potential me-
chanisms of the antitumor efficacy of panobinostat alone
or in combination with chemotherapy.
We found that panobinostat was highly effective in the
vast majority of NSCLC, SCLC, and Meso cell lines, of both
murine and human origin. Panobinostat at nanomolar con-
centrations inhibited the growth of all but one cancer cell
line. This efficacy seemed superior to SAHA, which gener-
ally required micromolar concentrations for similar effects
(Table 1).
Of particular interest was the high sensitivity of SCLC
lines to panobinostat. The median LD50 was 120 nmol/L
for NSCLC cell lines and 60 nmol/L for mesothelioma cell
lines, but was only 12 nmol/L for SCLC cell lines. Although
our findings of HDACi efficacy in NSCLC cell lines were
generally consistent with those previously reported for pa-
nobinostat (33, 43) and MGCD0103 (21), we are not aware of
previous analyses of panobinostat efficacy in a panel of
SCLC cell lines. The in vitro susceptibility of SCLC cell lines
to panobinostat we found (Table 1) was confirmed when the
in vivo susceptibility to panobinostat of tumors derived
from all four different SCLC cell lines tested was shown.
In contrast to only slowing tumor growth seen after pano-
binostat treatment of animals with NSCLC and mesothelio-
ma tumors, we noted substantial tumor regressions or
stabilization in three of the four human SCLC xenografts
and a substantial effect in the tumors from the remaining
H69 SCLC cell line (Fig. 3). In addition, the in vivo efficacy
of panobinostat may be even more enhanced when given
with chemotherapy. Although this report may be the first
to show in vivo data of HDACi efficacy against SCLC, we
note that others previously found susceptibility of a small
number of SCLC cell lines to other HDACi such as trichos-
tatin A (22, 26), FR901228 (27, 29), or valproic acid (32).
Our in vivo experiments also included analyses of pro-
tein status and expression in tumors derived from SCLC
cells that were grown in mice that were then separated in-
to treatment groups (consisting of mice that were mock-
treated and mice that were treated with panobinostat
alone, etoposide alone, or the two drugs in combination).
These analyses found evidence of anti-HDAC enzyme ac-
tivity, with increased acetylation of histones H3 and H4 af-
ter treatment of the animals with panobinostat. However,
we also found that panobinostat resulted in increased le-
vels of the proapoptotic factors t-Bid, cleaved PARP,
cleaved caspase 3, and cleaved caspase 7, accompanied
by the disappearance of Bcl-XL and an increase in levels
of the cyclin-dependent kinase (cdk) inhibitor p21. Our re-
sults may supply the first in vivo confirmation of modula-
tion of these proteins, which has been described only
previously in cells grown and treated under in vitro condi-
tions (16–18, 21, 22, 27, 29, 31, 34, 35, 43, 44). Thus, the
proapoptotic effects of HDACi that have been observed
for cells in culture are also likely to be operative in animal
models of SCLC. It should be noted that our analysis was
not exhaustive and that other pathways of cell death or
growth inhibition are also likely involved (32). Nonethe-
less, our observations suggest that a subset of these pro-
teins that are modulated by panobinostat may merit
testing as potentially useful biomarkers of HDACi efficacy
in clinical trials.
The striking effects of panobinostat on the Bcl-2 pathway
and related components may help explain why SCLC cell
lines are especially sensitive to this agent. The literature
Figure 4. The combination of panobinostat and etoposide has enhanced in vivo effects on SCLC cells growing in the mice. Graph shows in vivo ex-
periment where H69 SCLC tumor cells were injected in the flank of SCID mice (murine xenograft model) on day 0. Panobinostat treatment was started
when tumors reached approximately 200 mm3. Groups were as follows: control, no treatment provided (vehicle only); panobinostat, 20 mg/kg panobino-
stat administered 5 d weekly i.p.; etoposide, 40 mg/kg administered i.p. once weekly × 2; combination, etoposide 40 mg/kg plus panobinostat 20 mg/kg
administered i.p. *, P < 0.05 between control and panobinostat 20 mg/kg and combo (by ANOVA on day 23) and between panobinostat 20 mg/kg and
combo (day 27). Arrows from “Etoposide” box point to days when Etoposide treatment was administered. Arrow from “Panobinostat started” box indicates
when panobinostat treatment was started.
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supports the idea that SCLC, more than NSCLC or mesothe-
liomas, have high levels of expression of Bcl-2 and seem es-
pecially “addicted” to this pathway (45). For example, the
highly potent Bcl-2 inhibitors ABT-737 and ABT-263 exhib-
ited single-agent activity in in vitro and animal models of
SCLC and hematologic malignancies, but not in the major-
ity of other tumor types (46, 47). This Bcl-2 sensitivity has
resulted in SCLC being the primary target for a recent clin-
ical trial using a Bcl-2 antisense oligonucleotide (48).
Given the potentially different mechanisms of action and
toxicities, the proven value of multitargeted approaches in
cancer, the experimental data showing the interactions of
histone deacetylase with DNA topoisomerase II (15, 16),
and a report showing the combinatorial action of the HDA-
Ci trichostatin Awith etoposide (23), we examined the com-
bination of panobinostat with the topoisomerase inhibitor
and SCLC chemotherapy agent etoposide (VP16). The com-
bination of the two agents increased the ability to induce
apoptosis in H69 cells in vitro (Fig. 1B). The combination
seemed to work in an additive fashion in the in vivo H69
animal xenograft model (Fig. 4). Analysis of the tumor biop-
sies using immunoblotting that allowed comparison of the
effects with panobinostat alone, etoposide alone, or the
combination, showed what also seemed to be “additive” ef-
fects, in that in the combination there was enhanced loss of
Bcl-2 and an augmented increase in p21 compared with ei-
ther treatment alone (Fig. 5).
The combination of panobinostat and etoposide in-
creased the ability to induce apoptosis in H69 cells in cul-
ture and as a tumor xenograft in the mouse. In the
immunoblotting studies, however, the combination of
these two agents did not increase the expression of cleaved
caspase 3, caspase 7, PARP, and acetylated H4 compared
with panobinostat treatment only. There may be two po-
tential explanations for this seeming contradiction. First,
there may be differences between in vitro and in vivo ef-
fects. In vivo, panobinostat may inhibit angiogenesis or
other microenvironment-related mechanisms that contrib-
ute to tumor growth and treatment resistance, thereby sen-
sitizing the tumor to etoposide-induced mitotic death and
inhibition of tumor growth, as shown in Fig. 4. These me-
chanisms would not be in play for in vitro experiments
such as shown in Fig. 1. Second, the combination of pano-
binostat and etoposide led to levels of p21 that were sub-
stantially increased over either drug alone, as shown in
Fig. 5. The combination of the drugs also led to levels of
Bcl-2 that were maximally decreased to almost undetect-
able levels, in contrast to levels with either drug alone.
Consequently, it is also possible that panobinostat modu-
lates intracellular components beyond caspase activation,
to sensitize cancer cells to killing by etoposide.
Our ability to study murine cell lines grown in syngene-
ic mice allowed us to examine the question of whether pa-
nobinostat exerted any of its antitumor efficacy via
immune effects mediated by T or B cells. The effect of
HDACi on antitumor immunity is complex. On one hand,
HDACi have been reported to up-regulate MHC class I
and class II molecules (36), MHC class I–related chain A
and B (MICA/B) molecules (38), and TRAIL (49–51), all
of which could potentially enhance antitumor immune ef-
fects. On the other hand, these agents have been reported
to inhibit dendritic cell differentiation and immunogenicity
(52) and can stimulate the production of T-regulatory CD4
cells (53), all of which would inhibit antitumor immune
effects and promote tumor growth. In the TC-1 lung
cancer model, in which we have previously shown some
endogenous antitumor immune response (54), and in the
AE17-ova mesothelioma model, panobinostat had virtually
identical antitumor efficacy in normal compared with
immune-deficient mice (Supplementary Fig. S1), suggest-
ing no acquired immune response component to the activ-
ity seen. We did not study the effect of panobinostat with
active immunotherapy, however. This might be interesting,
because at least one report suggests that combining an
HDACi with immunotherapy (i.e., interleukin-2) could be
helpful (37).
In summary, panobinostat in nanomolar concentrations
seems to have activity against cell lines and tumors de-
rived from human NSCLC, SCLC, and mesothelioma. Cell
lines and tumors derived from SCLC seem to be especially
susceptible to the antigrowth effects of panobinostat, and
maximal efficacy was noted when combined with etopo-
side. Animal studies suggest that this agent causes histone
Figure 5. Effects of panobinostat, etoposide, or combined treatment on
key proteins in SCLC cells growing in the mouse: In vivo effects on core
histone acetylation, cell-cycle and apoptosis-related component. Analysis
of H69 tumors from in vivo combination therapy experiment shown in
Fig. 4. Tumor lysates from control (control) mice or mice treated with
panobinostat (panobinostat), etoposide (etoposide), or the combination
of panobinostat and etoposide (combo) were analyzed by immunoblot
with indicated antibodies. Protein concentrations were normalized accord-
ing to actin and tubulin levels.
Molecular Cancer Therapeutics
Mol Cancer Ther 2009;8(8). August 2009
2229
acetylation within tumors and results in nonimmunologi-
cally induced tumor cell apoptosis with acceptable toxicity.
SCLC remains a deadly form of lung cancer (1). Given the
high relapse rate after chemotherapy and the relative
dearth of second line treatments, these data support
clinical trials incorporating panobinostat for treatment
of SCLC.
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